Review of mesenchymal stem cells and tumors: Executioner or coconspirator?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 6, 2009, Pages 717-721

  Feng, Bing ^a,b   Chen, Longbang ^b  

^a NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Mesenchymal stem cells (MSCs); Tumor microenvironment; Tumor targeted therapy

Indexed keywords

CHEMOKINE RECEPTOR; DNA; INTERLEUKIN RECEPTOR; LYMPHOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIGEN PRESENTING CELL; BIOLOGICAL THERAPY; CANCER GROWTH; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL BASED GENE THERAPY; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; DNA MODIFICATION; IMMUNOGENICITY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL; MESENCHYMOMA; METASTASIS; MICROENVIRONMENT; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW;

ANTIGEN-PRESENTING CELLS; CARCINOGENS; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; FEMALE; FETAL BLOOD; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NEOPLASM METASTASIS; NEOPLASMS; PLACENTA; PREGNANCY;

EID: 73649091784     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0652     Document Type: Review

References (43)

1. Dominici M, Le BK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315.
2. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143.
3. Majumdar MK, Keane-Moore M, Buyaner D, et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. Biomed Sci 2003;10:228.
4. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41.
5. Henschler R, Deak E, Seifried E. Homing of mesenchymal stem cells. Transfus Med Hemother 2008;35:306.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860.
7. Honczarenko M, Lea Y, Swierkowski M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24:1030.
8. Menon LG, Picinich S, Koneru R, et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 2007;25:520.
9. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Exp Med 2006;203:1235.
10. Djouad F, Bony C, Apparailly F, et al. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006;82:1060.
11. Lu YR, Yuan Y, Wang XJ, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008;7:245.
12. Etheridge SL, Spencer GJ, Heath DJ, et al. Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 2004;22:849.
13. Romieu MR, Francois M, Boivin MN, et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. Immunol 2007;179:1549.
14. Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 2008;26:1275.
15. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297.
16. Ma B, Ren J, Jiang HF, et al. Antitumor activities against hepatocellular carcinoma induced by bone marrow mesenchymal stem cells pulsed with tumor-derived exosomes. Beijing Da Xue Xue Bao 2008;40:494.
17. Studeny M, Marini FC, Champlin RE, et al. Bone marrow derived mesenchymal stem cells as vehicles for interferonbeta delivery into tumors. Cancer Res 2002;62:3603.
18. Li X, Lu Y, Huang W, et al. In vitro effect of adenovirusmediated human gamma-interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol 2006;24:151.
19. Chen XC, Wang R, Zhao X, et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis 2006;27:2434.
20. Kucerova L, Altanerova V, Matuskova M, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007;67:6304.
21. Hong X, Masahiko K, Hiroyuki M, et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007;25:1618.
22. Ren C, Kumar S, Chanda D. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008;15: 1446.
23. Chen X, Lin X, Zhao J, et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008;16:749.
24. Kanehira M, Xin H, Hoshino K, et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 2007;14:894.
25. Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007;105:157.
26. Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. Neurooncology 2007;83:241.
27. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557.
28. Corcoran KE, Trzaska KA, Fernandes H, et al. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS ONE 2008;3:e2563.
29. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837.
30. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815.
31. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821.
32. Angoulvant D, Clerc A, Benchalal S, et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004;41:469.
33. Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006;107:1484.
34. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367.
35. Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cellderived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008;12:4991.
36. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94:678.
37. Zacharek A, Chen J, Cui X, et al. Angiopoietin1=Tie2 and VEGF=Flk1 induced by MSCS treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab 2007;27:1684.
38. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035.
39. Serakinci N, Guldberg P, Burns JS, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004;23:5095.
40. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568.
41. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371.
42. Rubio D, Garcia S, De la Cueva T, et al. Human mesenchymal stem cell transformation is associated with a mesenchymal- epithelial transition. Expe Cell Res 2008;314:691.
43. Marta C, Á ngel MC, David S, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffold. Stem Cells 2009; 27:753.